10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
12.80
+0.14 (1.11%)
At close: Aug 7, 2025, 4:00 PM
13.50
+0.70 (5.47%)
After-hours: Aug 7, 2025, 7:59 PM EDT
Regulus Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts that cover Regulus Therapeutics stock have a consensus rating of "Buy" and an average price target of $13.23, which forecasts a 3.36% increase in the stock price over the next year. The lowest target is $6.50 and the highest is $18.
Price Target: $13.23 (+3.36%)
Analyst Consensus: Buy
* Price targets were last updated on Jun 26, 2025.
Analyst Ratings
The average analyst rating for Regulus Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 8 | 8 | 7 | 7 | 7 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 16 | 16 | 15 | 15 | 15 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Hold Maintains $12 → $13 | Hold | Maintains | $12 → $13 | +1.56% | Jun 26, 2025 |
| Barclays | Barclays | Buy Maintains $12 → $13 | Buy | Maintains | $12 → $13 | +1.56% | Jun 24, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $26 → $18 | Buy | Maintains | $26 → $18 | +40.62% | May 19, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $14 | Buy | Reiterates | $14 | +9.37% | May 15, 2025 |
| UBS | UBS | Hold Maintains $14 → $12 | Hold | Maintains | $14 → $12 | -6.25% | May 13, 2025 |
Financial Forecast
Revenue This Year
593.99M
from 610.79M
Decreased by -2.75%
Revenue Next Year
627.26M
from 593.99M
Increased by 5.60%
EPS This Year
-1.22
from -1.52
EPS Next Year
-0.95
from -1.22
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 639.4M | 703.8M | 805.7M | ||
| Avg | 594.0M | 627.3M | 687.0M | ||
| Low | 560.2M | 569.4M | 614.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.7% | 18.5% | 28.4% | ||
| Avg | -2.7% | 5.6% | 9.5% | ||
| Low | -8.3% | -4.1% | -2.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.04 | -0.46 | -0.02 | ||
| Avg | -1.22 | -0.95 | -0.71 | ||
| Low | -1.54 | -1.23 | -1.11 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.